Zacks Research Issues Pessimistic Outlook for ENSC Earnings

Ensysce Biosciences, Inc. (NASDAQ:ENSC) – Equities researchers at Zacks Research reduced their Q3 2026 EPS estimates for shares of Ensysce Biosciences in a research note issued on Thursday, August 6th. Zacks Research analyst B. Sorensen now forecasts that the company will earn $0.04 per share for the quarter, down from their prior forecast of $0.09. The consensus estimate for Ensysce Biosciences’ current full-year earnings is ($1.53) per share. Zacks Research also issued estimates for Ensysce Biosciences’ Q4 2026 earnings at ($0.29) EPS, FY2026 earnings at ($1.27) EPS and FY2027 earnings at ($0.05) EPS.

A number of other equities research analysts also recently weighed in on the company. Wall Street Zen upgraded Ensysce Biosciences to a “hold” rating in a research report on Saturday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ensysce Biosciences in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has an average rating of “Sell”.

Ensysce Biosciences Price Performance

Ensysce Biosciences stock opened at $0.43 on Tuesday. Ensysce Biosciences has a 12-month low of $0.23 and a 12-month high of $2.75. The stock has a market capitalization of $6.62 million, a PE ratio of -0.13 and a beta of 0.84. The firm has a 50 day simple moving average of $0.29 and a 200-day simple moving average of $0.42.

Ensysce Biosciences (NASDAQ:ENSC) last released its earnings results on Friday, May 15th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.21. The firm had revenue of $0.96 million for the quarter, compared to analysts’ expectations of $1.00 million. Ensysce Biosciences had a negative net margin of 250.39% and a negative return on equity of 766.45%.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Virtu Financial LLC bought a new stake in shares of Ensysce Biosciences during the 3rd quarter worth $34,000. Citadel Advisors LLC acquired a new stake in shares of Ensysce Biosciences during the third quarter worth $34,000. DRW Securities LLC lifted its holdings in shares of Ensysce Biosciences by 42.4% during the fourth quarter. DRW Securities LLC now owns 98,481 shares of the company’s stock valued at $91,000 after purchasing an additional 29,336 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. lifted its holdings in shares of Ensysce Biosciences by 100.4% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 149,711 shares of the company’s stock valued at $138,000 after purchasing an additional 75,000 shares during the last quarter. Institutional investors own 5.63% of the company’s stock.

Ensysce Biosciences Company Profile

Ensysce Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel prodrug therapies aimed at improving pain management and addressing opioid misuse. Leveraging its proprietary prodrug platform, the company designs drug candidates that convert into active pharmaceuticals through specific enzymatic action, providing controlled-release profiles and built-in abuse deterrence features.

The company’s lead product candidate, ENS100, is an investigational oral prodrug of hydrocodone engineered to reduce the potential for misuse and abuse compared to immediate-release opioid formulations.